Tilray Inc (NASDAQ:TLRY - Get Free Report)'s share price was down 2.4% on Friday . The stock traded as low as $0.74 and last traded at $0.74. Approximately 9,635,211 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 45,825,211 shares. The stock had previously closed at $0.76.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group raised their price objective on Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $2.70.
Get Our Latest Research Report on TLRY
Tilray Trading Down 7.0 %
The firm's 50 day moving average price is $1.13 and its 200-day moving average price is $1.42. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. The stock has a market cap of $640.79 million, a P/E ratio of -2.28 and a beta of 2.07.
Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.07). The business had revenue of $210.90 million during the quarter, compared to the consensus estimate of $216.34 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The firm's revenue was up 8.7% on a year-over-year basis. As a group, equities research analysts forecast that Tilray Inc will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Tilray
Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in shares of Tilray by 1,314.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company's stock valued at $3,202,000 after acquiring an additional 1,690,827 shares during the last quarter. Tidal Investments LLC boosted its holdings in Tilray by 9.2% in the fourth quarter. Tidal Investments LLC now owns 10,595,264 shares of the company's stock worth $14,092,000 after purchasing an additional 889,086 shares during the last quarter. Quinn Opportunity Partners LLC boosted its holdings in Tilray by 108.0% in the fourth quarter. Quinn Opportunity Partners LLC now owns 1,618,080 shares of the company's stock worth $2,152,000 after purchasing an additional 840,000 shares during the last quarter. Virtu Financial LLC bought a new stake in Tilray in the 4th quarter worth approximately $1,029,000. Finally, Dimensional Fund Advisors LP raised its stake in Tilray by 54.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,172,935 shares of the company's stock valued at $2,890,000 after buying an additional 769,569 shares during the last quarter. 9.35% of the stock is currently owned by institutional investors.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Further Reading
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
